Skip to main content
. 2023 Nov 16;14:7421. doi: 10.1038/s41467-023-42997-7

Fig. 1. The layout of this study.

Fig. 1

Design of this study. NSCLC non-small cell lung cancer, RCC renal cell carcinoma, OS overall survival, PFS progression-free survival, irAEs immune-related adverse events. RECIST response evaluation criteria in solid tumors.